Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shu Sen Wang

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Annals of Translational Medicine|August 29, 2022
Age at initial diagnosis and prognosis of breast cancer: a nationwide multicenter retrospective study in ChinaHuan Yang, Qu-Chang Ouyang, Min Yan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 2, 2025
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA TrialRuo-Xi Hong, Fei Xu, Wen Xia, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 28, 2022
Perceived Importance of Breast Cancer Risk Factors: A Survey on 386 Physicians in ChinaLouis Wing-Cheong Chow, Pei-Fen Fu, Lei Guo, et al.
Frontiers in Oncology|February 10, 2023
Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective studyJin-Hu Fan, Su Zhang, Huan Yang, et al.
Journal of Oncology|September 27, 2021
Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from ChinaYi-Qun Han, Zong-Bi Yi, Pei Yu, et al.
International Journal of Cancer|July 24, 2020
Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological studyZong-Bi Yi, Pei Yu, Su Zhang, et al.
JAMA|December 10, 2020
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical TrialXi Wang, Shu-Sen Wang, Heng Huang, et al.
Breast Cancer (Dove Medical Press)|April 17, 2024
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 TrialYing Chen, Wen-Xia Li, Jia-Hua Wu, et al.
Cancer Cell|December 5, 2025
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrialLei Fan, Wen-Juan Zhang, Hui-Ping Li, et al.
Breast Cancer Research and Treatment|December 13, 2017
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III studyJie Xie, Jun Cao, Jing-Fen Wang, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Annals of Translational Medicine|August 29, 2022
Age at initial diagnosis and prognosis of breast cancer: a nationwide multicenter retrospective study in ChinaHuan Yang, Qu-Chang Ouyang, Min Yan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 2, 2025
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA TrialRuo-Xi Hong, Fei Xu, Wen Xia, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 28, 2022
Perceived Importance of Breast Cancer Risk Factors: A Survey on 386 Physicians in ChinaLouis Wing-Cheong Chow, Pei-Fen Fu, Lei Guo, et al.
Frontiers in Oncology|February 10, 2023
Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective studyJin-Hu Fan, Su Zhang, Huan Yang, et al.
Journal of Oncology|September 27, 2021
Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from ChinaYi-Qun Han, Zong-Bi Yi, Pei Yu, et al.
International Journal of Cancer|July 24, 2020
Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological studyZong-Bi Yi, Pei Yu, Su Zhang, et al.
JAMA|December 10, 2020
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical TrialXi Wang, Shu-Sen Wang, Heng Huang, et al.
Breast Cancer (Dove Medical Press)|April 17, 2024
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 TrialYing Chen, Wen-Xia Li, Jia-Hua Wu, et al.
Cancer Cell|December 5, 2025
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrialLei Fan, Wen-Juan Zhang, Hui-Ping Li, et al.
Breast Cancer Research and Treatment|December 13, 2017
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III studyJie Xie, Jun Cao, Jing-Fen Wang, et al.
Pageof 6